Cyclo (CKLIIF) (TFA)
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 2.6 and 2.2 μM, respectively[1].
Product Specifications
UNSPSC
12352209
Target
HIF/HIF Prolyl-Hydroxylase
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cyclo-ckliif-tfa.html
Purity
98.07
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H]1CC2=CC=CC=C2)=O)=O)=O)=O)[C@H](CS)NC1=O.O=C(O)C(F)(F)F
Molecular Formula
C38H60F3N7O8S
Molecular Weight
831.99
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CCNB3, phosphorylated (S286) (Ccnb3, Cycb3, G2/mitotic-specific cyclin-B3) (Biotin) discontinued